Skip to content
PulseMS
Log inJoin
Research & community

MS research, together.

MS research in plain English. Perspectives from people who understand.

Ranked by evidence, not popularity

Significant MS research developments

The strongest evidence added in the last 30 days. How we rank these

  1. Late-stage clinical trialAI summary · not yet reviewed

    Human Study of Remibrutinib for Relapsing Multiple Sclerosis

    These results suggest remibrutinib could be an effective new oral treatment option for relapsing multiple sclerosis, offering a possible improvement over existing therapies.

    Phase 3 · Randomised · 2,007 participants · Primary endpoint met · Peer-reviewed journal · Significance 83/100

  2. Review of studies in peopleAI summary · not yet reviewed

    Effects of Anti-CD20 Monoclonal Antibodies in Human Multiple Sclerosis

    This systematic review confirms that anti-CD20 therapies can provide substantial benefits in terms of relapse prevention and MRI markers of disease activity in patients with relapsing multiple sclerosis.

    Randomised · 5,911 participants · Primary endpoint met · Peer-reviewed journal · Significance 71/100

  3. Early-stage clinical trialAI summary · not yet reviewed

    Effects of Pilates Training Combined with Whole-Body Vibration in Human Subjects with MS

    These findings suggest that integrating whole-body vibration with Pilates may enhance rehabilitation for balance and mobility in MS patients, an area needing effective strategies.

    Phase 2 · Randomised · 34 participants · Primary endpoint met · Peer-reviewed journal · Significance 70/100

Research evidence filters

Filters apply to published research with a structured evidence assessment, including clearly labelled summaries that have not yet had human review. Unknown dates and unassessed posts are excluded when a corresponding filter is active.

Reset filters
Topics & sourcesExplore
Research and community updates, newest first.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedPublished in a peer-reviewed journal

Corneal Confocal Microscopy (CCM) in Patients With Central Neurodegenerative Disease

Research shows that CCM can detect changes in corneal nerve fiber characteristics and immune cell populations in patients, which correlate with disease severity and progression.

What this does not proveThe research is limited by small sample sizes, potential variability in how images are interpreted, and challenges in distinguishing between similar neurodegenerative conditions.
#MSResearch
View abstract on PubMedPMID 42920457AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyCase reportPublished in a peer-reviewed journal

Clinical Relapse Observed in Human MS Patient After Gamma Knife Radiosurgery

In a single case report, a human patient with multiple sclerosis (MS) experienced clinical relapse following gamma knife radiosurgery (GKRS) for meningioma. MRI scans revealed new gadolinium-enhancing lesions in both cerebral hemispheres seven months after the procedure, with additional lesions observed one month later, correlating with the relapse.

What this does not proveThe findings are based on a single patient case report, which limits their generalizability and does not establish causation.
#MSResearch
View abstract on PubMedPMID 42920560AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPublished in a peer-reviewed journal

Human Counseling Practices in Neurologic Care

In a study of 994 outpatient neurologic encounters, 38% included any documented counseling. Counseling focused more on medication and disease-specific education rather than lifestyle guidance, with headache specialists offering the most (73%) and cognitive/multiple sclerosis specialists offering the least (15%/11%).

What this does not proveThe study shows variability in documentation of counseling without establishing its effectiveness or impact on patient outcomes.
#MSResearch
View abstract on PubMedPMID 42920594AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedPublished in a peer-reviewed journal

Mitochondrial Biomarkers in Human Neurological Disorders

Mitochondrial dysfunction is identified as a common issue in neurological disorders, including multiple sclerosis. Studies show that mitochondrial biomarkers can enhance diagnostic accuracy and help in monitoring disease progression and treatment response.

What this does not proveDespite potential benefits, clinical use of these biomarkers is hindered by variability and lack of specificity.
#MSResearch
View abstract on PubMedPMID 42919989AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyCase reportPublished in a peer-reviewed journal

Food Insecurity in Patients with Multiple Sclerosis and Rheumatoid Arthritis

A study found that 65% of patients with multiple sclerosis (MS) experienced food insecurity (FI), compared to 37.5% of those with rheumatoid arthritis (RA) (p = 0.014). MS patients were more likely to report FI than those with RA (p = 0.028). Higher disability levels in MS patients were linked to increased FI (p = 0.019), and FI was associated with greater pain severity and interference.

What this does not proveThe study only examined MS and RA patients, which may limit the generalizability of the findings. Additionally, the cross-sectional design does not allow for causal conclusions.
#MSResearch
View abstract on PubMedPMID 42920280AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyPhase 3Published in a peer-reviewed journal

Human Study of Remibrutinib for Relapsing Multiple Sclerosis

In two Phase 3 clinical trials (REMODEL-1 and REMODEL-2) with 2007 participants, remibrutinib demonstrated a significantly lower annualised relapse rate (ARR) compared to teriflunomide. In REMODEL-1, the ARR was 0.073 for remibrutinib versus 0.112 for teriflunomide (RR 0.648, p=0.018). In REMODEL-2, the ARR rates were 0.080 vs 0.116 (RR 0.688, p=0.034).

What this does not proveThese trials are ongoing and not currently recruiting, meaning long-term effects and additional data on safety and efficacy are still pending.
#Other
View abstract on PubMedPMID 42915009AI summary of a published abstract. Not medical advice.